Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.12 USD | +2.17% | -0.28% | -19.85% |
May. 30 | Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma | MT |
May. 30 | Bristol Myers: FDA approval for Breyanzi | CF |
Chart: Technical Analysis
Technical analysis trends
Short Term | Mid-Term | Long Term | |
---|---|---|---|
Trend | Bearish | Bearish | Bearish |
Resistance | 45.06 | 47.84 | 50.89 |
Spread/Res. | -8.73% | -14.04% | -19.19% |
Spread/Supp. | +3.64% | +6.87% | +8.22% |
Support | 39.68 | 38.48 | 38.00 |
Technical Rankings Surperformance
Short Term Timing | |
---|---|
Middle Term Timing | |
Long Term Timing | |
RSI | |
Bollinger Spread | |
Unusual Volumes |
- Stock Market
- Equities
- BMY Stock
- Charts Bristol-Myers Squibb Company